Recent Developments in Combinatorial Immunotherapy towards Ovarian Cancer

Ovarian cancer is one of the most common cancers in women in the world. It is also the 5th top cause of cancer-related death in the world. Despite chemotherapy being the primary treatment along with surgery, patients frequently suffer from a recurrence of ovarian cancer within a few years of the original treatment. The recurring nature of OC, therefore, necessitates the development of novel therapeutic interventions that can effectively tackle this disease. Immunotherapy has lately been found to offer significant clinical advantages. Some of the immunotherapy techniques being studied for ovarian cancer include adoptive T-cell treatment, immune checkpoint inhibition, and oncolytic virus. However, the most efficient way to increase longevity is through a combination of immunotherapy strategies with other disease therapeutic approaches such as radiotherapy, chemotherapy, and PARPi in additive or synergistic ways. To provide a more comprehensive insight into the current immunotherapies explored, this paper explores newly developed therapeutics for the disease with an emphasis on current outstanding immunotherapy. The current state of our understanding of how the disease interacts with host cells, current therapy options available, various advanced treatments present and the potential for combinatorial immuno-based therapies in the future have also been explored.